Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC

Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC

10.1002/cpdd.427

Saved in:

Bibliographic Details
Main Authors:	Tan, Eng-Huat, Lim, Wan-Teck, Ahn, Myung-Ju, Ng, Quan-Sing, Ahn, Jin Seok, Tan, Daniel Shao-Weng, Sun, Jong-Mu, Han, May, Payumo, Francis C, Mckee, Krista, Yin, Wei, Credi, Marc, Agarwal, Shefali, Jac, Jaroslaw, Park, Keunchil
Other Authors:	DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
Format:	Article
Language:	English
Published:	WILEY 2022
Subjects:	Science & Technology Life Sciences & Biomedicine Pharmacology & Pharmacy ficlatuzumab NSCLC gefitinib lung adenocarcinoma non-small cell lung cancer CELL LUNG-CANCER ADVANCED SOLID TUMORS FACTOR RECEPTOR CLINICAL-SIGNIFICANCE SCATTER-FACTOR RESISTANCE MET MUTATIONS ERLOTINIB ADENOCARCINOMA
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/218636
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

Similar Items

Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer
by: Wong, A.S., et al.
Published: (2014)

Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma
by: Verma, Akash, et al.
Published: (2017)

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials
by: Ku, G.Y., et al.
Published: (2016)

Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung
by: De Lima Lopes Jr., G., et al.
Published: (2016)

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
by: Tan, Wan-Ling, et al.
Published: (2022)

Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant
by: Soon, Jonathan Jian Hao, et al.
Published: (2023)

How many adenocarcinoma lung cancers come from bronchioloalveolar carcinoma?
by: Wong, A.S., et al.
Published: (2014)

Rare subtypes of adenocarcinoma of the lung
by: Ou, S.-H.I., et al.
Published: (2014)

EGFR S1166 phosphorylation induced by a combination of EGF and gefitinib has a potentially negative impact on lung cancer cell growth
by: Assiddiq, B.F., et al.
Published: (2014)

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
by: Yeo, W.-L., et al.
Published: (2011)

The Role of nitric oxide in apoptotic susceptibility of human lung cancer and normal lung cells
by: Pithi Chanvorachote
Published: (2008)

EGFR Mutant Structural Database: Computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib
by: Ma, L, et al.
Published: (2020)

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
by: Sudo, M., et al.
Published: (2014)

NATURAL KILLER CELL BASED THERAPY FOR LUNG CANCER
by: AMIT JAIN
Published: (2022)

Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy
by: Soo, R.A., et al.
Published: (2014)

Glycosylated and non-glycosylated quantum dot-displayed peptides trafficked indiscriminately inside lung cancer cells but discriminately sorted in normal lung cells: An indispensable part in nanoparticle-based intracellular drug delivery
by: Tan, Roger Salvacion
Published: (2018)

Dapithapon: A short feature on lung cancer disease patients and quality of life
by: Martin, Francesca Anne D., et al.
Published: (2016)

RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status
by: Omar, M.F.M., et al.
Published: (2014)

Phosphoproteins from lung cancer cell A549
by: Atchara Rubporn
Published: (2011)

Primary acinic cell carcinoma of the lung : the first case report in Thailand
by: Yavarace Vongsivavilas, et al.
Published: (2006)

In-home coal and wood use and lung cancer risk: A pooled analysis of the international lung cancer consortium
by: Dean Hosgood, H., et al.
Published: (2014)

THE ONCOGENIC ROLE OF TREFOIL FACTOR 3 (TFF3) IN NON-SMALL CELL LUNG CANCER (NSCLC)
by: ZHANG MENGYI
Published: (2019)

REPROGRAMMING OF HUMAN LUNG CANCER CELLS TO PLURIPOTENCY WITH DEFINED FACTORS AND THEIR CHARACTERIZATION
by: KONG CHIOU MEE
Published: (2015)

Effects of artonin e on lung cancer cell anoikis
by: Ekkarat Wongpankam
Published: (2014)

Effects of ecteinascidin 770 on lung cancer NCI-H23 cell anoikis
by: Phattrakorn Powan
Published: (2014)

Bergamottin suppresses metastasis of lung cancer cells through abrogation of diverse oncogenic signaling cascades and epithelial-to-mesenchymal transition
by: Ko J.-H., et al.
Published: (2019)

Symptom clusters and their influences on the functional status in advanced lung cancer patients receiving chemotherapy
by: Thidarat Khamboon
Published: (2023)

Comparison of clinical with pathological nodal staging from systematic mediastinal lymph node dissection in early resectable non-small cell lung cancer
by: Chong, C.F., et al.
Published: (2011)

A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer
by: Soo, R.A., et al.
Published: (2014)

A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer
by: Soo, R.A., et al.
Published: (2011)

Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: A phase II study in Caucasian and Asian patients
by: Millward, M.J., et al.
Published: (2016)

Non-small cell lung cancer presenting with neoplastic fever at diagnosis and relapse
by: Zee, Y.K., et al.
Published: (2014)

Commuting and exposure to airborne carcinogenic materials : a case study of Bangkok air pollution
by: Priyakamon Khan, et al.
Published: (2006)

Increased risk of lung cancer in individuals with a family history of the disease: A pooled analysis from the International Lung Cancer Consortium
by: Coté, M.L., et al.
Published: (2014)

A hospital based case-control study on risk factors for lung cancer among Thai males
by: Devkota, Uma Nath, 1952-
Published: (2023)

EFFECTIVENESS OF LUNG CANCER SCREENING USING LOW-DOSE COMPUTED TOMOGRAPHY AMONG MALE CHRONIC SMOKERS: A SYSTEMATIC REVIEW AND META-ANALYSIS
by: SARAH FOO XIAO HAN
Published: (2019)

Application of survival analysis techniques on lung cancer patient data in the Philippines with censored observations
by: Arthur, John Alexander O., et al.
Published: (2010)

Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial
by: Schuler, M, et al.
Published: (2024)

Lung cancer incidence in Singapore: Ethnic and gender differences
by: Lim, W.-Y., et al.
Published: (2014)

Reproductive factors and lung cancer risk: A comprehensive systematic review and meta-analysis
by: Yin, X., et al.
Published: (2021)